FoxM1 in tumor cell
FoxM1 in tumor cell
批准号:
10004294
负责人:
Pradip Raychaudhuri
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-10-01 至 2024-03-31
关键词:
Antineoplastic AgentsBindingCRISPR/Cas technologyCell CycleCell TherapyChronicClinicDevelopmentDiagnosisDifferentiated GeneDiseaseDrug resistanceEpigenetic ProcessG1 PhaseGenerationsGenesGenetic RecombinationGenetic TranscriptionHeadHepatocyteHumanHybridsInjuryKnock-in MouseLinkLiverLiver RegenerationMaintenanceMalignant NeoplasmsMalignant neoplasm of liverMediatingModelingMolecularMouse StrainsMusNeoplasm MetastasisPathway interactionsPhosphorylationPlayPopulationPrimary carcinoma of the liver cellsProtein FamilyRecoveryRepressionResearchResistanceRoleSiteTestingTherapeuticTimeTranscriptional ActivationTransgenic ModelTransplantationTreatment EfficacyVeteransbasecancer cellcancer stem cellchronic liver diseasechronic liver injuryliver functionmimeticsmutantneoplastic cellnoveloutcome forecastoverexpressionpluripotencystemstem-like celltumor progressionweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. Often the disease is diagnosed at a
late stage of high-grade cancer progression that is resistant to the available therapies. HCC is also a significant
problem among the Veterans. According to VA Research Currents (Mike Richman, 2017, VA website) the outlook
for hepatocellular carcinoma among the US Veterans is bleak, as it is increasing at a rate about five times greater
than that of general US population. A 2015 study indicated that HCC among US Veterans is going peak in the
year of 2021. Clearly, a greater understanding of the molecular mechanisms underlying HCC will be important
for development of efficacious therapeutic strategies. This proposal focuses on the fork-head box M1 (FoxM1)
gene because it is essential for HCC development and progression. Also, overexpression of FoxM1 in HCC
predicts poor prognosis. FoxM1 has been extensively studied as an activator of genes involved in proliferation,
pluripotency, and metastasis. Recently, we discovered a repression function of FoxM1. In this proposal we will
investigate the hypothesis is that the newly discovered repression function of FoxM1 plays critical roles in the
development and progression of HCC.
We are using a Ras-transgenic model for HCC, mainly because the Ras-pathway is ubiquitously activated in
human HCC through epigenetic silencing of its regulators. Using that model, we showed that conditional deletion
of FoxM1 after HCC development causes preferential loss of the liver cancer stem cells (LCSCs). Interestingly,
we observed that FoxM1 represses the liver differentiation gene FoxA2. Repression of FoxA2 by FoxM1 involves
interactions of FoxM1 with the Rb-family proteins, and it occurs in G1 phase of the cell cycle. We will investigate
the hypothesis that G1 phase repression of FoxM1 is important for the mechanism by which FoxM1 supports the
liver cancer stem cells. We have developed a novel knock-in mouse strain that expresses a mutant FoxM1
deficient in the repression function, but retains its ability to activate transcription. That strain will be used to
investigate the significance of the repression function in liver cancer development and liver cancer stem cells. In
addition, using that knock-in mouse strain, we will determine whether the repression function of FoxM1 is
important for recovery from chronic liver injury. The specific aims are:
1. Investigate the G1 phase repression function of FoxM1 in maintenance of the liver cancer stem cells.
2. Investigate the repression function of FoxM1 in HCC development and progression.
3. Investigate whether the repression function of FoxM1 is important for recovery from chronic liver
injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repression function of FoxM1 in metastasis
-
批准号:9910845
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2019
-
负责人:Pradip Raychaudhuri
-
依托单位:
Repression function of FoxM1 in metastasis
-
批准号:10229508
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2019
-
负责人:Pradip Raychaudhuri
-
依托单位:
Repression function of FoxM1 in metastasis
-
批准号:10020378
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2019
-
负责人:Pradip Raychaudhuri
-
依托单位:
Repression function of FoxM1 in metastasis
-
批准号:10460966
-
项目类别:
-
资助金额:$35.85万
-
财政年份:2019
-
负责人:Pradip Raychaudhuri
-
依托单位:
Repression function of FoxM1 in metastasis
-
批准号:10670759
-
项目类别:
-
资助金额:$35.85万
-
财政年份:2019
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in liver cancer.
-
批准号:8787994
-
项目类别:
-
资助金额:$40.51万
-
财政年份:2014
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in breast cancer.
-
批准号:8848358
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2014
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in breast cancer.
-
批准号:9251769
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2014
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:9339464
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:8195570
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:8394585
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:7912927
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:10456026
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:10620198
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
FoxM1 in tumor cell
-
批准号:7793253
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Pradip Raychaudhuri
-
依托单位:
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
-
批准号:7174582
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2007
-
负责人:Pradip Raychaudhuri
-
依托单位:
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
-
批准号:7616958
-
项目类别:
-
资助金额:$3.58万
-
财政年份:2007
-
负责人:Pradip Raychaudhuri
-
依托单位:
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
-
批准号:7760669
-
项目类别:
-
资助金额:$22.58万
-
财政年份:2007
-
负责人:Pradip Raychaudhuri
-
依托单位:
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
-
批准号:8018494
-
项目类别:
-
资助金额:$27.79万
-
财政年份:2007
-
负责人:Pradip Raychaudhuri
-
依托单位:
Cell Penetrating Peptide Inhibitor of FoxM1 in Hepatocellular Carcinoma Treatment
-
批准号:7558987
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2007
-
负责人:Pradip Raychaudhuri
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: